Shinobi Therapeutics has been awarded up to $59 million in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). The funds will support the development of Shinobi's lead iPS-T cell programme targeting GPC3+ tumours. Shinobi also announced an extension of its Series A round, bringing the company's total funding to $119 […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!